FUS/TLS Genetic Markers for ALS Diagnosis and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods for amyotrophic lateral sclerosis (ALS) are inadequate in identifying genetic predispositions and effectively managing the disease, as they fail to account for mutations in the FUS/TLS gene, which are associated with both dominant and recessive forms of ALS.
Innovation Solution
Developing methods for diagnosing ALS by detecting specific genetic markers in the FUS/TLS gene, such as C1551G, C1561G, G1542T, and others, and using siRNA or expression vectors to modulate mutant FUS/TLS activity, thereby providing therapeutic options for delaying or preventing the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then diagnosis can be performed, but genetic predispositions and FUS/TLS gene mutations cannot be identified
Solution Approach 1:
The patent introduces specific genetic markers (C1551G, C1561G, G1542T, G1543T, C1561T, G1562A, A1564G, G1572C) as intermediaries to detect FUS/TLS gene mutations. These markers serve as detectable indicators that bridge the gap between current diagnostic capabilities and the underlying genetic causes of ALS, enabling identification of both dominant and recessive forms of the disease.
Solution Approach 2:
The patent replaces conventional diagnostic approaches with molecular genetic analysis methods. By substituting traditional clinical diagnostic mechanisms with direct genetic marker detection in FUS/TLS gene, the system achieves comprehensive identification of genetic predispositions and mutations that were previously undetectable.
2Reliability
If conventional treatment methods are used, then general management is provided, but effective management of FUS/TLS-related ALS cannot be achieved
Solution Approach 1:
The patent enables treatment customization by identifying specific genetic mutations in the FUS/TLS gene. Different genetic markers (C1551G, C1561G, G1542T, etc.) correspond to different mutation types, allowing treatments to be tailored to the specific genetic profile of each patient. This local quality approach ensures that therapeutic interventions are adapted to the precise genetic characteristics of the disease manifestation.
Solution Approach 2:
The patent changes the fundamental parameter of treatment selection from symptomatic-based to genotype-based. By detecting specific genetic markers and mutation patterns in FUS/TLS gene, the treatment approach transitions to modifying therapeutic parameters according to the specific genetic alteration present, thereby achieving both reliability and adaptability.
3Loss of time
If passive treatment approach is used, then disease progression is managed, but proactive prevention cannot be implemented
Solution Approach 1:
The patent implements preliminary action by detecting FUS/TLS gene mutations and genetic markers before clinical symptoms manifest or at early disease stages. By identifying mutations such as C1551G, C1561G, G1542T, and others through genetic testing, the system enables preventive interventions and early management strategies that can potentially delay or prevent disease progression, rather than merely responding to established symptoms.
Data Source
AI summary
The invention provides novel FUS/TLS nucleic acids and proteins that comprise one or more genetic markers (for example, single nucleotide polymorphisms) and methods of use thereof including methods relating to the diagnosis of ALS or other related motor neuron disease by virtue of the presence of the mutant FUS/TLS sequence(s).